# Evaluating the Safety and Immune Response to Two Doses of a Dengue Virus Vaccine Administered 12 Months Apart

> **NCT01782300** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 48 (estimated)

## Conditions studied

- Dengue

## Interventions

- **BIOLOGICAL:** TV003 Vaccine
- **BIOLOGICAL:** Placebo Vaccine

## Key facts

- **NCT ID:** NCT01782300
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2015-03
- **Final completion:** 2016-09
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2017-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01782300

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01782300, "Evaluating the Safety and Immune Response to Two Doses of a Dengue Virus Vaccine Administered 12 Months Apart". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT01782300. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*